(Il Sole 24 Ore Radiocor) - Milano, 31 mar - Biogen said that the closing of the acquisition of Apellis is expected in the second quarter of 2026.

In 2025, Empaveli and Syfovre had combined sales of 689 million dollars, and are expected to grow at a rate in the mid-to-high teens at least through 2028, it added.

The transaction is expected to be "increasingly accretive" to.

Biogen's adjusted diluted EPS starting in 2027.

(RADIOCOR) 31-03-26 14:31:12 (0487) 5 NNNN